BR112017015206A2 - síntese de um inibidor de tirosina quinase de bruton - Google Patents
síntese de um inibidor de tirosina quinase de brutonInfo
- Publication number
- BR112017015206A2 BR112017015206A2 BR112017015206A BR112017015206A BR112017015206A2 BR 112017015206 A2 BR112017015206 A2 BR 112017015206A2 BR 112017015206 A BR112017015206 A BR 112017015206A BR 112017015206 A BR112017015206 A BR 112017015206A BR 112017015206 A2 BR112017015206 A2 BR 112017015206A2
- Authority
- BR
- Brazil
- Prior art keywords
- synthesis
- tyrosine kinase
- kinase inhibitor
- bruton tyrosine
- bruton
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562103507P | 2015-01-14 | 2015-01-14 | |
| US62/103,507 | 2015-01-14 | ||
| PCT/US2016/013424 WO2016115356A1 (en) | 2015-01-14 | 2016-01-14 | Synthesis of a bruton's tyrosine kinase inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112017015206A2 true BR112017015206A2 (pt) | 2018-06-19 |
| BR112017015206B1 BR112017015206B1 (pt) | 2023-04-11 |
Family
ID=56406389
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112017015206-1A BR112017015206B1 (pt) | 2015-01-14 | 2016-01-14 | Processos para a preparação de 1-((r)-3-(4-amino-3-(4- fenoxifenil)-1h- pirazol[3,4-d]pirimidin-1-il)piperidin-1-il)prop-2- en-1-ona (ibrutinibe) e compostos |
Country Status (16)
| Country | Link |
|---|---|
| US (5) | US20180009814A1 (pt) |
| EP (1) | EP3245208A4 (pt) |
| JP (2) | JP2018502077A (pt) |
| KR (1) | KR20170102887A (pt) |
| CN (2) | CN107108640A (pt) |
| AU (2) | AU2016206693A1 (pt) |
| BR (1) | BR112017015206B1 (pt) |
| CA (2) | CA3210320A1 (pt) |
| HK (1) | HK1246293A1 (pt) |
| IL (3) | IL308276A (pt) |
| MA (1) | MA41350A (pt) |
| MX (2) | MX366827B (pt) |
| RU (1) | RU2017128308A (pt) |
| SG (2) | SG11201705678YA (pt) |
| WO (1) | WO2016115356A1 (pt) |
| ZA (1) | ZA201704338B (pt) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107207519B (zh) * | 2015-02-12 | 2019-11-08 | 正大天晴药业集团股份有限公司 | 伊布替尼的制备方法 |
| US11883404B2 (en) | 2016-03-04 | 2024-01-30 | Taiho Pharmaceuticals Co., Ltd. | Preparation and composition for treatment of malignant tumors |
| KR20240014585A (ko) | 2016-03-04 | 2024-02-01 | 다이호야쿠힌고교 가부시키가이샤 | 악성 종양 치료용 제제 및 조성물 |
| CN109206426B (zh) * | 2017-07-06 | 2021-10-08 | 上海复星星泰医药科技有限公司 | 吡唑并嘧啶类化合物的制备方法 |
| WO2019027860A1 (en) | 2017-08-01 | 2019-02-07 | Boehringer Ingelheim International Gmbh | INTERMEDIATE COMPOUNDS AND METHODS |
| CN107814804A (zh) * | 2017-10-27 | 2018-03-20 | 广州科锐特生物科技有限公司 | 依鲁替尼的制备方法 |
| WO2019181876A1 (ja) | 2018-03-19 | 2019-09-26 | 大鵬薬品工業株式会社 | アルキル硫酸ナトリウムを含む医薬組成物 |
| CA3098497A1 (en) | 2018-05-03 | 2019-11-07 | Juno Therapeutics, Inc. | Combination therapy of a chimeric antigen receptor (car) t cell therapy and a kinase inhibitor |
| JP6944496B2 (ja) * | 2018-10-22 | 2021-10-06 | ファイザー・インク | ピロロ［２，３−ｄ］ピリミジントシル酸塩、その結晶形態、ならびにその製造方法および中間体 |
| KR20210088651A (ko) | 2018-11-09 | 2021-07-14 | 다이호야쿠힌고교 가부시키가이샤 | 디메톡시벤젠 화합물의 제조 방법 |
| CN109988175A (zh) * | 2019-04-28 | 2019-07-09 | 梯尔希（南京）药物研发有限公司 | 一种依鲁替尼-d5的制备方法 |
| AU2020280904A1 (en) * | 2019-05-21 | 2021-11-18 | Janssen Pharmaceutica Nv | Processes and intermediates for preparing a BTK inhibitor |
| BR112021022347A2 (pt) * | 2019-05-21 | 2022-01-04 | Janssen Pharmaceutica Nv | Processos e intermediários para a preparação de um inibidor de btk |
| US20240092785A1 (en) | 2021-01-21 | 2024-03-21 | Synthon B.V. | Process for making ibrutinib |
| CN114853662B (zh) * | 2021-02-05 | 2024-01-12 | 四川青木制药有限公司 | 手性肼基哌啶衍生物的制备方法 |
| WO2023220655A1 (en) | 2022-05-11 | 2023-11-16 | Celgene Corporation | Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy |
| WO2023242384A1 (en) | 2022-06-17 | 2023-12-21 | Krka, D.D., Novo Mesto | Crystalline form of ibrutinib |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4550214A (en) * | 1981-01-05 | 1985-10-29 | Polaroid Corporation | Blocked vinyl biphenyl compounds |
| US4874822A (en) * | 1988-04-07 | 1989-10-17 | Minnesota Mining And Manufacturing Company | Process for the acrylamidoacylation of alcohols |
| EP2228369A1 (en) * | 2003-12-23 | 2010-09-15 | Astex Therapeutics Ltd. | Pyrazole derivatives as protein kinase modulators |
| EP2201840B1 (en) * | 2006-09-22 | 2011-11-02 | Pharmacyclics, Inc. | Inhibitors of Bruton's Tyrosine Kinase |
| EP2954900A1 (en) * | 2007-03-28 | 2015-12-16 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
| US7741330B1 (en) * | 2009-10-12 | 2010-06-22 | Pharmacyclics, Inc. | Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase |
| WO2014022390A1 (en) * | 2012-07-30 | 2014-02-06 | Concert Pharmaceuticals, Inc. | Deuterated ibrutinib |
| CN103121999A (zh) * | 2012-08-29 | 2013-05-29 | 苏州迪飞医药科技有限公司 | 一种酪氨酸激酶抑制剂pci-32765的合成方法 |
| US9156847B2 (en) * | 2013-03-15 | 2015-10-13 | Janssen Pharmaceutica Nv | Processes and intermediates for preparing a medicament |
| US8957080B2 (en) * | 2013-04-09 | 2015-02-17 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
| CN103626774B (zh) * | 2013-11-20 | 2015-11-04 | 苏州明锐医药科技有限公司 | 伊鲁替尼的制备方法 |
| CN105471823B (zh) * | 2014-09-03 | 2018-10-26 | 阿里巴巴集团控股有限公司 | 一种敏感信息处理方法、装置、服务器及安全判定系统 |
| US10266535B2 (en) * | 2015-01-21 | 2019-04-23 | Hefei Institutes Of Physical Science, Chinese Academy Of Sciences | Inhibitor of FLT3 kinase and use thereof |
-
2016
- 2016-01-13 MA MA041350A patent/MA41350A/fr unknown
- 2016-01-14 WO PCT/US2016/013424 patent/WO2016115356A1/en active Application Filing
- 2016-01-14 CA CA3210320A patent/CA3210320A1/en active Pending
- 2016-01-14 SG SG11201705678YA patent/SG11201705678YA/en unknown
- 2016-01-14 AU AU2016206693A patent/AU2016206693A1/en not_active Abandoned
- 2016-01-14 CA CA2971460A patent/CA2971460C/en active Active
- 2016-01-14 CN CN201680005456.4A patent/CN107108640A/zh active Pending
- 2016-01-14 SG SG10201906517VA patent/SG10201906517VA/en unknown
- 2016-01-14 RU RU2017128308A patent/RU2017128308A/ru not_active Application Discontinuation
- 2016-01-14 CN CN202110485400.6A patent/CN113816962A/zh active Pending
- 2016-01-14 JP JP2017532649A patent/JP2018502077A/ja active Pending
- 2016-01-14 MX MX2017009154A patent/MX366827B/es active IP Right Grant
- 2016-01-14 US US15/542,848 patent/US20180009814A1/en not_active Abandoned
- 2016-01-14 BR BR112017015206-1A patent/BR112017015206B1/pt active IP Right Grant
- 2016-01-14 KR KR1020177019206A patent/KR20170102887A/ko not_active Application Discontinuation
- 2016-01-14 IL IL308276A patent/IL308276A/en unknown
- 2016-01-14 EP EP16737886.8A patent/EP3245208A4/en not_active Withdrawn
-
2017
- 2017-06-19 IL IL253020A patent/IL253020A0/en unknown
- 2017-06-26 ZA ZA2017/04338A patent/ZA201704338B/en unknown
- 2017-07-12 MX MX2019008815A patent/MX2019008815A/es unknown
-
2018
- 2018-05-07 HK HK18105861.5A patent/HK1246293A1/zh unknown
- 2018-12-18 US US16/224,425 patent/US20190367518A1/en not_active Abandoned
-
2019
- 2019-12-04 US US16/703,344 patent/US20200347064A1/en not_active Abandoned
-
2020
- 2020-05-17 IL IL274716A patent/IL274716A/en unknown
- 2020-09-11 AU AU2020230323A patent/AU2020230323A1/en not_active Abandoned
- 2020-10-09 JP JP2020171454A patent/JP2021035947A/ja active Pending
-
2021
- 2021-02-17 US US17/177,852 patent/US20220098200A1/en not_active Abandoned
-
2023
- 2023-06-14 US US18/209,939 patent/US20240158400A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| MX2019008815A (es) | 2019-09-26 |
| HK1246293A1 (zh) | 2018-09-07 |
| US20190367518A1 (en) | 2019-12-05 |
| SG10201906517VA (en) | 2019-08-27 |
| EP3245208A4 (en) | 2018-10-17 |
| IL274716A (en) | 2020-07-30 |
| AU2020230323A1 (en) | 2020-10-01 |
| MX2017009154A (es) | 2017-10-12 |
| WO2016115356A1 (en) | 2016-07-21 |
| US20240158400A1 (en) | 2024-05-16 |
| MX366827B (es) | 2019-07-25 |
| US20200347064A1 (en) | 2020-11-05 |
| US20220098200A1 (en) | 2022-03-31 |
| CA2971460C (en) | 2023-10-10 |
| US20180009814A1 (en) | 2018-01-11 |
| IL253020A0 (en) | 2017-08-31 |
| BR112017015206B1 (pt) | 2023-04-11 |
| KR20170102887A (ko) | 2017-09-12 |
| JP2018502077A (ja) | 2018-01-25 |
| CN113816962A (zh) | 2021-12-21 |
| RU2017128308A (ru) | 2019-02-14 |
| SG11201705678YA (en) | 2017-08-30 |
| MA41350A (fr) | 2017-11-21 |
| JP2021035947A (ja) | 2021-03-04 |
| CA3210320A1 (en) | 2016-07-21 |
| CA2971460A1 (en) | 2016-07-21 |
| RU2017128308A3 (pt) | 2019-10-24 |
| CN107108640A (zh) | 2017-08-29 |
| IL308276A (en) | 2024-01-01 |
| ZA201704338B (en) | 2023-10-25 |
| AU2016206693A1 (en) | 2017-07-13 |
| EP3245208A1 (en) | 2017-11-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112017015206A2 (pt) | síntese de um inibidor de tirosina quinase de bruton | |
| BR112017002231A2 (pt) | novas formulações de um inibidor de tirosina cinase de bruton | |
| BR112017018931A2 (pt) | formulações farmacêuticas de um inibidor de tirosina quinase de bruton | |
| MA42623A (fr) | Inhibiteurs de la tyrosine kinase de bruton | |
| DK3303334T3 (da) | Tyrosinkinasehæmmere | |
| MA42242A (fr) | Inhibiteurs de la tyrosine kinase | |
| BR112017020743A2 (pt) | cocristais de um inibidor da tirosina cinase de bruton. | |
| IL248546B (en) | A multi-fluorinated compound as an inhibitor of proton tyrosine kinase | |
| DK3365334T3 (da) | Benzolactamforbindelser som proteinkinaseinhibitorer | |
| CL2016002502A1 (es) | Inhibidores de biaril cinasa | |
| MA43162A (fr) | Inhibiteurs de type imidazopyrazine de tyrosine kinase de bruton | |
| DK3160956T3 (da) | Inhibitorer af lysin-specifik demethylase-1 | |
| DK3511319T3 (da) | Hæmmere af lysinspecifik demethylase-1 | |
| DK3831833T3 (da) | Fremgangsmåder til fremstillingen af en pi3k-inhibitor | |
| EP3141546A4 (en) | Inhibitor of bruton's tyrosine kinase | |
| DK3448846T3 (da) | Syntese af indazoler | |
| DK3290418T3 (da) | Janus Kinase (JAK)-hæmmere | |
| LT3386991T (lt) | Policikliniai junginiai, kaip brutono tirozinkinazės inhibitoriai | |
| BR112017020744A2 (pt) | formas solvadas de um inibidor de tirosina quinase de bruton. | |
| DK3371165T3 (da) | Btk-inhibitor til anvendelse til behandling af kræft | |
| DK3448849T3 (da) | Syntese af indazoler | |
| FR3042983B1 (fr) | Reflux de colonnes de demethanisation | |
| MA44607A (fr) | Inhibiteurs de kinase | |
| HK1226070B (zh) | 酪氨酸蛋白激酶抑制劑 | |
| DK3380453T3 (da) | Syntese af beta-mercaptoethanol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B15K | Others concerning applications: alteration of classification |
Free format text: A CLASSIFICACAO ANTERIOR ERA: C07D 487/04 Ipc: C07D 487/04 (2006.01), A61K 31/519 (2006.01), A61P |
|
| B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] |
Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021 |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B154 | Notification of filing of divisional application [chapter 15.50 patent gazette] |
Free format text: O PEDIDO FOI DIVIDIDO NO BR122022026564-2 PROTOCOLO 870220121728 EM 23/12/2022 17:40. |
|
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/01/2016, OBSERVADAS AS CONDICOES LEGAIS |